CD274 and melanoma: However, clinical trials in melanoma have shown that the combination of Nivolumab (αPD-1) and Ipilimumab (αCTLA-4) can restore the therapeutic effects of Nivolumab and extend progression-free survival in patients with negative PD-L1, compared with those treated with Nivolumab alone (173, 174).